语言

China

中国 地图

查看印度查看巴西

省份

请在下方的农业企业信息库中进行搜索

行业

位置: 中国 - Zhejiang - 行业- - ALPHA NUCLIDE (NINGBO) MEDICAL TECHNOLOGY CO., LTD.

  • 公司名称: ALPHA NUCLIDE (NINGBO) MEDICAL TECHNOLOGY CO., LTD.

  • 联系人:

  • 电话:

  • 行业: 实验室 Laboratory

  • 地址: Building 43#, NO.136, Yuhai East Rd., Hangzhou Bay Dist., Ningbo, Zhejiang, 315336 China

  • E-mail:

  • Company category:

  • 员工数量:

  • 网站地址:

  • Last updated: 2026-03-23

纳税人编号:

营收:

公司介绍 ：

Alpha Nuclide (Ningbo) Medical Technology Co., Ltd. was established in 2020 and is one of the founding members of the World Astatine Community initiated by the European Cooperation in Science and Technology (serving as China's sole representative). The core technical team consists of returnees from renowned international universities such as Duke University and the University of Missouri. The team specializes in the production and R&D of medical radionuclides and radiopharmaceuticals, leveraging globally advanced Astatine-211 (At-211) technology to provide integrated diagnostic and therapeutic solutions for diseases. The company's R&D headquarters is located in the Hangzhou Bay New Area, Ningbo, Zhejiang Province, and has obtained the Zhejiang Provincial "Radiation Safety License" and "Laboratory Animal Use License." Its East China production base (Zhejiang Alpha Nuclide Medical Technology Co., Ltd.) and North China production base (Hebei Alpha Nuclide Medical Technology Co., Ltd.) were established in 2022 and 2025 in Jiaxing Haiyan and Shijiazhuang Economic Development Zone, respectively. These bases have deployed one 30MeV proton cyclotron and two 30MeV alpha cyclotrons (the only such facilities in China). The East China production base has completed all pre-operational preparations and is set to commence operations by 2026, commercially supplying the alpha radionuclide At-211 and other scarce medical isotopes for research and clinical needs. By 2028, the Alpha Nuclide Group is expected to establish a new landscape driven by multiple domestic and international bases, with coordinated production and full utilization of regional advantages, further strengthening the development of alpha radionuclide pharmaceuticals.

公司产品：